Tango Therapeutics (TNGX) Consolidated Net Income (2020 - 2026)

Tango Therapeutics' Consolidated Net Income history runs 7 years deep, the most recent figure standing at -$45.5 million for Q1 2026.

• In Q1 2026, Consolidated Net Income fell 14.14% year-over-year to -$45.5 million; the TTM figure through Mar 2026 stood at -$107.2 million (up 18.93% YoY), while the FY2025 annual figure was -$101.6 million, up 22.03% from the prior year.
• Consolidated Net Income was -$45.5 million for Q1 2026 at Tango Therapeutics, down from -$38.7 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of $15.9 million in Q3 2025 to a low of -$45.5 million in Q1 2026.
• Historically, Consolidated Net Income has averaged -$28.7 million across 5 years, with a median of -$29.1 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Consolidated Net Income slumped 453.26% in 2022, then soared 154.46% in 2025.
• A 5-year view of Consolidated Net Income shows it stood at -$29.1 million in 2022, then fell by 5.86% to -$30.8 million in 2023, then fell by 22.29% to -$37.6 million in 2024, then dropped by 2.89% to -$38.7 million in 2025, then declined by 17.58% to -$45.5 million in 2026.
• The last three Consolidated Net Income figures came in at -$45.5 million (Q1 2026), -$38.7 million (Q4 2025), and $15.9 million (Q3 2025), per Business Quant data.